Spyre Therapeutics
SYRE
60 hedge funds and large institutions have $123M invested in Spyre Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 9 closing their positions.
163% more capital inflows, than outflows
Capital inflows: $23.2M | Capital outflows: $8.82M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2.07% more ownership
Funds ownership: 66.36% → 68.43% (+2.1%)
2% more funds holding
Funds holding: 59 → 60 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.61M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$2.76M |
| 3 |
Ritholtz Wealth Management
New York
|
+$2.47M |
| 4 |
BlackRock
New York
|
+$2.33M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.54M |
| 2 |
Jennison Associates
New York
|
-$1.53M |
| 3 |
Man Group
London,
United Kingdom
|
-$1.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$519K |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$451K |
SYRE Hedge Fund Activity: Q4 2018 in Review
60 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2018, worth a combined $123M — down 12% from $140M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SYRE positions and 9 closed out — a net gain of 1 holder — while 18 added to existing stakes and 16 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.61M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.54M sold.
- 60 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2018, up from 59 in Q3 2018.
- Funds reported $123M of Spyre Therapeutics stock for Q4 2018, down 12% quarter-over-quarter.
- 10 funds opened new Spyre Therapeutics positions in Q4 2018 and 9 closed out, a net change of +1 holder.
- The largest Spyre Therapeutics buyer in Q4 2018 was Adage Capital Partners, an estimated $4.61M added.
- The largest Spyre Therapeutics seller in Q4 2018 was Point72 Asset Management, an estimated $2.54M sold.
Based on aggregated 13F filings for Q4 2018.